FDA approves rituximab for advanced follicular lymphoma

February 2011
Hem/Onc Today;2/25/2011, Vol. 12 Issue 4, p3
The article reports on the approval of the drug rituximab by the U.S. Food and Drug Administration (FDA) for the treatment for advanced follicular lymphoma.


Related Articles

  • Re-treatment strategy challenges maintenance therapy for rituximab use in low-burden FL.  // Hem/Onc Today;12/25/2011, Vol. 12 Issue 24, p58 

    The article discusses the results of a study by Brad S. Kahl of the University of Wisconsin which suggests the challenge posed by re-treatment strategy to maintenance therapy for rituximab use in low-burden follicular lymphoma (FL).

  • CORAL: Rituximab-containing regimens produced similar outcomes.  // Hem/Onc Today;9/10/2010, Vol. 11 Issue 17, p22 

    The article discusses research on the overall survival, progression-free survival (PFS) and event-free survival of patients with diffuse large B-cell lymphoma who received rituximab regimens, by C. Gisselbrecht and colleagues, published in the 2010 issue of the "Journal of Clinical Oncology."

  • Maintenance rituximab and radioimmunotherapy cost effective.  // PharmacoEconomics & Outcomes News;Mar2015, Vol. 724 Issue 1, p16 

    The article reports that a U.S. study has found that maintenance treatment with rituximab and radioimmunotherapy (RIT) are cost effective for advanced follicular lymphoma.

  • Rituximab induction looks good in asymptomatic follicular lymphoma.  // PharmacoEconomics & Outcomes News;May2015, Vol. 727 Issue 1, p28 

    The article discusses research being done on the use of frontline rituximab monotherapy induction versus wait and watch approach for asymptomatic advanced-stage follicular lymphoma, which references a study by A. Prica et al. published in the April 15, 2015 issue of the journal "Cancer."

  • Rituximab pays off long term.  // PharmacoEconomics & Outcomes News;1/23/2010, Issue 595, p3 

    The article discusses research on the cost effectiveness of rituximab maintenance therapy in follicular lymphoma, that references a study by E. Deconick and colleagues published in the January 1, 2010 issue of "PharmacoEconomics."

  • Rituximab plus epratuzumab effective in follicular lymphoma.  // Hem/Onc Today;11/10/2013, Vol. 14 Issue 21, p6 

    The article discusses a research paper on the efficiency of rituximab plus epratuzumab in treating follicular lymphoma, which references a study by Bruce D. Cheson et al., publishd in a 2013 issue of "Cancer."

  • Use of intravitreal rituximab for treatment of vitreoretinal lymphoma. Kashani, Shahram // Current Medical Literature: Ophthalmology;2014, Vol. 24 Issue 1, p28 

    The article discusses the study "Use of Intravitreal Rituximab for Treatment of Vitreoretinal Lymphoma," by K. L. Larkin and colleagues in a 2014 issue of "British Journal of Ophthalmology."

  • I Tositumomab: A Viewpoint by Michael L. Grossbard. Grossbard, M.L. // BioDrugs;2000, Vol. 14 Issue 3, p203 

    Discusses the approval of an unconjugated anti-CD20 antibody rituximab for the treatment of patients with relapsed follicular and low grade non-Hodgkin's lymphoma. Use of monoclonal antibody therapies in laboratories; Conjugation of antibodies with radioisotopes to permit the targeted delivery...

  • First-line rituximab maintenance favourable in Finland.  // PharmacoEconomics & Outcomes News;7/9/2011, Issue 632, p7 

    This article discusses a study on the cost effectiveness of first-line rituximab maintenance for the treatment of patients with follicular lymphoma.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics